News

Add-on treatment with Diacomit (stiripentol) was associated with reductions in the number of episodes of status epilepticus (SE), periods of prolonged seizure activity, in people with Dravet syndrome and other types of epilepsy, a review study found. Evidence also suggested that Diacomit may be able to stop…

Two-thirds of 24 children and young adults with Dravet syndrome experienced clinically meaningful declines in seizure frequency after adding Fintepla (fenfluramine) to their treatment regimen, according to a real-world Danish analysis. Fintepla’s use also was associated with reductions in healthcare utilization and the use of other anti-seizure medications.

Longboard Pharmaceuticals has launched a Phase 3 clinical trial evaluating the efficacy and safety of bexicaserin, its investigational treatment for seizures associated with Dravet syndrome and other forms of developmental and epileptic encephalopathies, known as DEEs. The worldwide study, dubbed DEEp SEA, expects to enroll about 160…

Stoke Therapeutics’ zorevunersen, a treatment that addresses the genetic cause of Dravet syndrome, continues to reduce the frequency of seizures in children and adolescents who are taking part in Phase 1/2 clinical studies in the U.S. and the U.K., while also leading to improvements in cognition and behavior.

Nine months of treatment with bexicaserin (LP352), an investigational oral small molecule from Longboard Pharmaceuticals, more than halved the frequency of motor seizures in adults and adolescents with Dravet syndrome or other forms of developmental and epileptic encephalopathies (DEE). That’s according to new interim data from the…

The Dravet Syndrome Foundation (DSF) is partnering with the Mason’s Movement Foundation to provide bereavement support to families who have lost someone to Dravet syndrome. The partnership connects bereaved families to a Mason’s Movement initiative called the Good Mourning Project, which provides resources, support, and remembrance items…

The newly created DANCE checklist, to be completed by caregivers, may help diagnose additional conditions that often occur alongside Dravet syndrome by identifying non-seizure features — such as language, cognitive, and behavioral problems — seen with this type of epilepsy, according to a pilot study that tested the use…

Targeting a heart protein called NaV1.6 may help prevent sudden death in adults with Dravet syndrome, a study in mice suggests. The study, “Cardiac-Specific Deletion of Scn8a Mitigates Dravet Syndrome-Associated Sudden Death in Adults,” was published in JACC: Clinical Electrophysiology. Dravet syndrome is caused by…

The U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold on higher doses of zorevunersen, an experimental treatment for Dravet syndrome currently being tested in Phase 1/2 trials. The FDA placed the hold based on preclinical data in 2020, limiting dosing of zorevunersen in studies taking…

Parents of children with Dravet syndrome in Spain say they don’t get enough support to help meet the emotional and economic challenges of the disease, a study found. “The findings of this study underscore the need for policy reforms that specifically address the challenges faced not only by individuals…